Renaissance Technologies LLC Boosts Holdings in Aldeyra Therapeutics, Inc. $ALDX

Renaissance Technologies LLC boosted its holdings in shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 146.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 863,187 shares of the biotechnology company’s stock after acquiring an additional 513,187 shares during the period. Renaissance Technologies LLC owned about 1.43% of Aldeyra Therapeutics worth $1,459,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. 683 Capital Management LLC grew its position in Aldeyra Therapeutics by 86.6% in the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after acquiring an additional 710,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Aldeyra Therapeutics by 2.6% during the third quarter. Vanguard Group Inc. now owns 3,591,869 shares of the biotechnology company’s stock valued at $18,750,000 after acquiring an additional 90,276 shares during the period. Captrust Financial Advisors boosted its stake in shares of Aldeyra Therapeutics by 9.1% in the 2nd quarter. Captrust Financial Advisors now owns 51,492 shares of the biotechnology company’s stock valued at $197,000 after purchasing an additional 4,297 shares in the last quarter. Ameriprise Financial Inc. acquired a new stake in shares of Aldeyra Therapeutics in the 2nd quarter valued at $101,000. Finally, AQR Capital Management LLC grew its holdings in shares of Aldeyra Therapeutics by 275.4% in the 2nd quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock worth $5,645,000 after purchasing an additional 1,081,257 shares during the last quarter. Hedge funds and other institutional investors own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALDX. Weiss Ratings downgraded shares of Aldeyra Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 20th. Wall Street Zen raised Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.50.

Aldeyra Therapeutics Stock Performance

Shares of NASDAQ:ALDX opened at $1.52 on Thursday. The business has a fifty day moving average of $1.81 and a 200-day moving average of $2.64. Aldeyra Therapeutics, Inc. has a twelve month low of $1.07 and a twelve month high of $6.17. The firm has a market cap of $91.70 million, a PE ratio of -3.90 and a beta of 1.21.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.09) EPS for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, analysts anticipate that Aldeyra Therapeutics, Inc. will post -0.43 EPS for the current fiscal year.

Insider Activity

In other news, CEO Todd C. Brady purchased 250,000 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average price of $1.67 per share, with a total value of $417,500.00. Following the completion of the purchase, the chief executive officer directly owned 1,721,298 shares of the company’s stock, valued at $2,874,567.66. The trade was a 16.99% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.80% of the stock is owned by company insiders.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.